Novonesis increases outlook for full year 2024

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.

The 2024 outlook is increased to:

• Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7%”)

• Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously “35-36%”)

Additional information is made available in the Company announcement: Interim Report H1 2024.

Attachment

• 2024_26_Company_Announcement

You May Also Be Interested In

• Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
• Heidmar Maritime Holdings Corp. Reports Results for the Second Quarter Ended June 30, 2026
• Integrated Strategic Partners Announces Four New Senior Consultants